摘要
目的:基于整合药理学探讨柴胡-黄芩药对改善新型冠状病毒(COVID-19)临床症状的作用机制研究,为柴胡-黄芩药对的临床应用提供参考。方法:借助中药整合药理学平台(TCMIP V2.0),预测柴胡-黄芩改善COVID-19临床症状的关键靶点和作用通路,绘制"药对-活性成分-关键靶标-作用通路"多维网络图,从分子层面探讨其作用机制。结果:研究结果表明,柴胡-黄芩可能通过调控白介素信号通路、C型凝集素域7家族成员A(CLEC7A)/炎症途径、免疫应激等相关信号通路,达到抑制活化的细胞因子、缓和过激的免疫反应、消除炎症、抗病毒等相关作用,此外研究还发现柴胡-黄芩核心靶标:核因子κB(NFκB2、NFκB1)、白介素(IL-6、IL-1B)、Toll-样受体4(TLR4)、肿瘤坏死因子(TNF)等大多与炎症发生引起机体损伤相关。柴胡-黄芩药对具有抗炎、抗病毒、増强免疫力、抑制肺纤维化等临床疗效。结论:柴胡-黄芩可通过多途径、多靶点、多环节治疗COVID-19。本研究结果为柴胡-黄芩药对改善COVID-19的使用提供理论依据。
Objective:Novel coronavirus(COVID-19)was used to improve the clinical symptoms of the new type coronavirus(LV),based on integrated pharmacology.Methods:TCMIP v2.0 was used to predict the key target and action pathway of Bupleurum baicalensis Georgi in improving the clinical symptoms of covid-19.The multi-dimensional network diagram of"drug pair active component key target action pathway"was drawn to explore its action mechanism from the molecular level.Results:The results showed that Bupleurum and Scutellaria baicalensis could regulate IL signaling pathway and CLEC7A(a member of C-type lectin domain 7 family)/Inflammatory pathway,immune stress and other related signaling pathways can inhibit activated cytokines,alleviate excessive immune response,eliminate inflammation,and resist virus.In addition,the core targets of Bupleurum baicalensis baicalensis Georgi nuclear factorκB(NFκB2,NFκB1),interleukin(IL-6,IL-1B),toll like receptor 4(TLR4),tumor necrosis factor(TNF)and so on are mostly induced by inflammation.It is related to body damage.Bupleurum and scutellaria have the clinical effects of anti-inflammatory,antiviral,strengthening immunity,inhibiting pulmonary fibrosis and so on.Conclusion:Radix Bupleuri Scutellariae can be used to treat covid-19 by multi-channel,multi-target and multi ring.The results of this study provide a theoretical basis for Bupleurum Scutellaria to improve the use of covid-19.
作者
方欢乐
别蓓蓓
穆颖
刘荣利
陈衍斌
FANG Huan-le;BIE Bei-bei;MU Ying;LIU Rong-li;CHEN Yan-bin(Medical College of Xi' an Peihua University, Xi'an,Shaanxi 710125, China;Scientific research department of Shaanxi step Pharmaceutical Co., Ltd, Xi'an,Shaanxi 710075, China)
出处
《海南医学院学报》
CAS
2020年第12期895-900,共6页
Journal of Hainan Medical University
基金
陕西省重点研发计划项目(2018SF-279)
陕西省大学生创新创业项目(S201911400012)
咸阳市重大科技专项计划项目(2018K01-47)。
